Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 541-548

  Colombo, Giorgio L ^a   Di Matteo, Sergio ^a   Mir, Lluis M ^b,c  

^a SAVE Studi Analisi Valutazioni Economiche   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Chemotherapy; Cliniporator; Cost effectiveness; Cutaneous and subcutaneous tumors; Electrochemotherapy; Hyperthermia; Interferon alpha; Isolated limb perfusion; Radiotherapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELECTROCHEMOTHERAPY; HOSPITAL COST; HUMAN; HYPERTHERMIC THERAPY; INTERFERON INDUCTION; INTERMETHOD COMPARISON; LIMB PERFUSION; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; SKIN TUMOR; SUBCUTANEOUS TISSUE TUMOR;

EID: 44049099012     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. ASSR. 2007. Agenzia per i Servizi Sanitari Regionali [online]. URL: http://www.assr.it/spesasanitaria.htm#spesa_san
2. Balch CH, Buzaid A, et al. 2000. A new American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Cancer, 88:1484-91.
3. Falk MH, Issels LD. 2001. Hyperthermia in oncology. Int J Hyperthermia, 17:11-18.
4. Gabriele P, Orecchia R, et al. 1989. Clinical hyperthermia, alone or with radiation therapy: results of a preliminary study on recurrences of cancers. Arch Geschwulstforsch, 59:177-81.
5. Gaudy-Marqueste C, Regis JM, et al. 2006. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys, 65:809-16.
6. Gehl J, Skovsgaard T, Mir LM 1998. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs, 9:319-25.
7. Gothelf A, Mir LM, Gehl J. 2003. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev, 29:371-87.
8. Hahka-Kemppinen M, Muhonen T, et al. 1995. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol, 132:973-7.
9. Health Ministry. 2006. 2006 National Tariff Nomenclator. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale, Ministero della Salute.
10. Health Ministry. 2006. Hospital DRG tariffs, TUC, Tariffa Unica Convenzionale, National DRG Tariff.
11. Informatore Farmaceutico 2007. Medicinali, Publisher Masson-Elsevier.
12. Jaroszeski MJ, Coppola D, et al. 2001. Treatment of hepatocellular carcinoma in a rat model using f. Eur J Cancer, 37:422-30.
13. Kim JH, Hahn EW, et al. 1978. Combination hyperthermia and radation therapy for cutaneous malignant melanoma. Cancer, 41:2143-8.
14. Lienard D, Eggermont AM, et al. 1999. Isolated limb perfusion with tumor nercrosis factor alpha and melphalan with or without interferon-gamma for the treatment of in transit melanoma metastases: a multicenter randomized phase II study. Melanoma Res, 9:491-502.
15. Lynn G. Feun, Niramol Savaraj, et al. 2000. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer, 88:584-8.
16. Marty M, Sersa G, Garbay JR, et al. 2006. Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of the ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer, 4(Suppl):3-13
17. Meier F, Will S et al. 2002. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Brit J Dermatol, 147:62-70.
18. Mir LM, Gehl J, Sersa G, et al. 2006. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur J Cancer, 4(Suppl):14-25.
19. Mir LM, Glass LF, et al. 1998. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer, 77:2336-42.
20. Mughal TI, Thomas MR, et al. 1991. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology, 48:365-8.
21. Popov P, Tukiainen E, et al. 2004. Soft-tissue sarcomas of the upper extremity: Surgical treatment and outcome. Plast Reconstr Surg, 113:222-32.
22. Richtig E, Hoff M, et al. 2003. Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma. J Dtsch Dermatol Ges, 1:635-42.
23. Rossi CR, Foletto M, et al. 2004. Hypertermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and mephlan for bulky in-transit melanoma metastases. Ann Surg Oncol, 11:173-7.
24. Sersa G, Borut S, et al. 2000. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res, 6:863-7.
25. Sersa G, Cemazar M et al. 1995. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res, 55:3450-5.
26. Wolf IH, Richtig E, Kopera D, et al. 2004. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg, 30:244-7.
27. Wolf IH, Smolle J, et al. 2003. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol, 139:273-6.